Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes-Reference-Cited by-同舟云学术

Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes

Published:2022-08 Issue:8 Volume:28 Page:501.e1-501.e7
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Alatrash Gheath,Saberian Chantal,Bassett Roland^ORCID,Thall Peter F.,Ledesma Celina,Lu Yoshimi,Daher May,Valdez Benigno C.,Kawedia Jitesh^ORCID,Popat Uday,Mehta Rohtesh,Oran Betul,Nieto Yago,Olson Amanda,Anderlini Paolo,Marin David,Hosing Chitra,Alousi Amin M.,Shpall Elizabeth J.,Rondon Gabriela,Chen Julianne,Qazilbash Muzaffar,Champlin Richard E.,Kebriaei Partow

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference67 articles.

1. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes;Russell;Biol Blood Marrow Transplant,2002

2. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced- toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS;de Lima;Blood,2004

3. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin;Russell;Biol Blood Marrow Transplant,2007

4. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS;Andersson;Biol Blood Marrow Transplant,2008

5. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine;Lee;J Clin Oncol,2013

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current issues in dose-finding designs: A response to the US Food and Drug Adminstration’s Oncology Center of Excellence Project Optimus;Clinical Trials;2024-04-03

2. Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells;Frontiers in Oncology;2023-11-23

3. Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes;Clinical Cancer Research;2023-09-19

4. The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia;Best Practice & Research Clinical Haematology;2023-09

5. Generalized phase I‐II designs to increase long term therapeutic success rate;Pharmaceutical Statistics;2023-04-11